stockrowModerna, Inc.
MRNA Healthcare Biotechnology
Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.
- Revenue
- +2.11%
- EPS
- +7.51%
- Free cash flow
- +38.9%
- Total debt
- +1,765.6%
Quarter to June 2026, against a year earlier
Follow MRNA
Alert me
Moderna, Inc. (MRNA) Book value per share
Moderna, Inc.'s book value per share at the end of fiscal 2025 was 22.2×, down 21.7% from 28.4× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 17.0×. Over the past ten years it has ranged from −8.5× (fiscal 2017) to 48.5× (fiscal 2022); the current reading is higher than 60% of that period. Moderna, Inc. ranks 43rd of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 22.2× | (21.67%) |
| FY2024 | 28.4× | (21.72%) |
| FY2023 | 36.3× | (25.28%) |
| FY2022 | 48.5× | 38.28% |
| FY2021 | 35.1× | 422.17% |
| FY2020 | 6.7× | 89.38% |
| FY2019 | 3.5× | (81.19%) |
| FY2018 | 18.9× | — |
| FY2017 | −8.5× | — |
| FY2016 | −5.5× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 17.0× | (9.42%) |
| Mar 2026 | 18.8× | (15.66%) |
| Dec 2025 | 22.2× | (7.05%) |
| Sep 2025 | 23.9× | (1.24%) |
| 32 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | 329× |
| VRTX Vertex Pharmaceuticals Incorporated compare | 82.5× |
| RPRX Royalty Pharma PLC compare | 22.0× |
| MRNA Moderna, Inc. | 17.0× |
| RVMD Revolution Medicines, Inc. compare | 11.2× |
| GMAB Genmab A/S Sponsored ADR compare | 9.7× |
| ROIV Roivant Sciences Ltd. compare | 6.8× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 0.0× |
| ARGX argenex SE compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on MRNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement